trending Market Intelligence /marketintelligence/en/news-insights/trending/HbLoY7Zi0kX-VeIET9e2ow2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cumberland wins patent case involving Acetadote against Mylan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cumberland wins patent case involving Acetadote against Mylan

The U.S. Court of Appeals for the Federal Circuit ruled in favor of Cumberland Pharmaceuticals Inc. in a patent case involving its Acetadote product.

The court upheld the validity of the patent, which will remain in force until August 2025.

The ruling affirmed the Sep. 30, 2015, decision reached by the United States District Court for the Northern District of Illinois, in which the court upheld Cumberland's patent, rejecting a validity challenge from Mylan NV's Mylan Inc. and Mylan Institutional LLC.

Cumberland's patent that was challenged had claims associated with Acetadote's formulation that it is substantially free of chelating or stabilizing agents. Mylan infringed the patent by filing an abbreviated new drug application of its generic version of Acetadote.

On Oct. 30, 2015, Mylan filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit. The district court entered an order on Nov. 17, 2015, enjoining Mylan and its affiliates from selling or using its generic version of Acetadote until Cumberland's patent expires.

Acetadote is indicated for the treatment of acetaminophen poisoning in the U.S. Acetaminophen is a medication used to relieve pain and fever.